Compare TTRX & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTRX | SKYH |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 327.2M |
| IPO Year | 2025 | 2020 |
| Metric | TTRX | SKYH |
|---|---|---|
| Price | $9.84 | $10.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.00 | ★ $13.13 |
| AVG Volume (30 Days) | 46.1K | ★ 189.9K |
| Earning Date | 05-31-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 105.11 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,540,000.00 |
| Revenue This Year | N/A | $78.89 |
| Revenue Next Year | N/A | $73.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.57 |
| 52 Week Low | $2.57 | $8.22 |
| 52 Week High | $11.69 | $11.70 |
| Indicator | TTRX | SKYH |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 50.07 |
| Support Level | $2.81 | $10.13 |
| Resistance Level | $10.72 | $11.17 |
| Average True Range (ATR) | 0.62 | 0.40 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 55.41 | 30.84 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.